Gastrointestinal oncology
Oncolytics Biotech Inc. supports clinical research in advanced and metastatic gastrointestinal tumors, with a focus on cancers arising in the digestive tract.
- Gastrointestinal cancers
- Metastatic solid tumors
- Advanced disease
The sponsor’s research activity is centered on patients with difficult-to-treat gastrointestinal malignancies across multiple collaborating sites in Canada.
Immuno-oncology combinations
The clinical program examines immunotherapy combinations in gastrointestinal cancer, including approaches that pair atezolizumab with other anticancer treatments.
- Immune checkpoint inhibition
- Combination cancer therapy
- Tumor response assessment
These studies reflect interest in integrating immune-based treatment strategies with existing standard cancer care.
Oncolytic virotherapy
Research funded by the sponsor includes pelareorep, an oncolytic virus platform being explored in combination with other therapies for solid tumors.
- Oncolytic virus therapy
- Anticancer combination regimens
- Biomarker-informed research
This area of interest connects viral-based cancer treatment with immune-modulating strategies in gastrointestinal oncology.
Clinical response and tolerability
The sponsor’s trial portfolio places emphasis on safety, tolerability, and measures of antitumor activity in patients receiving combination treatment.
- Objective response
- Disease control
- Treatment tolerability
These endpoints are used to evaluate how well the studied therapies perform in patients with advanced gastrointestinal cancer.
